33 related articles for article (PubMed ID: 28485172)
1. FXR Regulates Intestinal Cancer Stem Cell Proliferation.
Fu T; Coulter S; Yoshihara E; Oh TG; Fang S; Cayabyab F; Zhu Q; Zhang T; Leblanc M; Liu S; He M; Waizenegger W; Gasser E; Schnabl B; Atkins AR; Yu RT; Knight R; Liddle C; Downes M; Evans RM
Cell; 2019 Feb; 176(5):1098-1112.e18. PubMed ID: 30794774
[TBL] [Abstract][Full Text] [Related]
2. Farnesoid X receptor induces cell death and sensitizes to TRAIL-induced inhibition of growth in colorectal cancer cells through the up-regulation of death receptor 5.
Hotta M; Sakatani T; Ishino K; Wada R; Kudo M; Yokoyama Y; Yamada T; Yoshida H; Naito Z
Biochem Biophys Res Commun; 2019 Nov; 519(4):824-831. PubMed ID: 31561852
[TBL] [Abstract][Full Text] [Related]
3. FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer Burden.
Joseph SC; Eugin Simon S; Bohm MS; Kim M; Pye ME; Simmons BW; Graves DG; Thomas-Gooch SM; Tanveer UA; Holt JR; Ponnusamy S; Sipe LM; Hayes DN; Cook KL; Narayanan R; Pierre JF; Makowski L
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611046
[TBL] [Abstract][Full Text] [Related]
4. Delineating the role of nuclear receptors in colorectal cancer, a focused review.
Manickasamy MK; Jayaprakash S; Girisa S; Kumar A; Lam HY; Okina E; Eng H; Alqahtani MS; Abbas M; Sethi G; Kumar AP; Kunnumakkara AB
Discov Oncol; 2024 Feb; 15(1):41. PubMed ID: 38372868
[TBL] [Abstract][Full Text] [Related]
5. Interpretation of Farnesoid X Receptor Immunohistochemical Expression in Discriminating Hepatocellular Carcinoma from Its Non-Neoplastic Mimics as an Adjunct to Glypican 3.
Salama DEA; Shash LS; Shakweer MM; Abdel-Maqsoud RR; Ahmed Abosaif AI; Elgohary SA
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3221-3227. PubMed ID: 37774075
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Receptors and Lipid Sensing.
Thorne JL; Cioccoloni G
Adv Exp Med Biol; 2022; 1390():83-105. PubMed ID: 36107314
[TBL] [Abstract][Full Text] [Related]
7. Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer.
Girisa S; Henamayee S; Parama D; Rana V; Dutta U; Kunnumakkara AB
Mol Biomed; 2021 Jul; 2(1):21. PubMed ID: 35006466
[TBL] [Abstract][Full Text] [Related]
8. The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity.
Anderson KM; Gayer CP
Cells; 2021 Nov; 10(11):. PubMed ID: 34831429
[TBL] [Abstract][Full Text] [Related]
9. The Nuclear Farnesoid X Receptor Reduces p53 Ubiquitination and Inhibits Cervical Cancer Cell Proliferation.
Huang X; Wang B; Chen R; Zhong S; Gao F; Zhang Y; Niu Y; Li C; Shi G
Front Cell Dev Biol; 2021; 9():583146. PubMed ID: 33889569
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X receptor: a potential therapeutic target in multiple organs.
Zhang C; Wang Z; Feng Q; Chen WD; Wang YD
Histol Histopathol; 2020 Dec; 35(12):1403-1414. PubMed ID: 33393073
[TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis.
Yu J; Li S; Guo J; Xu Z; Zheng J; Sun X
Cell Death Dis; 2020 Aug; 11(8):640. PubMed ID: 32807788
[TBL] [Abstract][Full Text] [Related]
12. Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.
Absil L; Journé F; Larsimont D; Body JJ; Tafforeau L; Nonclercq D
BMC Cancer; 2020 Jul; 20(1):640. PubMed ID: 32650752
[TBL] [Abstract][Full Text] [Related]
13. Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.
Sipe LM; Chaib M; Pingili AK; Pierre JF; Makowski L
Immunol Rev; 2020 May; 295(1):220-239. PubMed ID: 32320071
[TBL] [Abstract][Full Text] [Related]
14. Expression of FXR and HRG and their clinicopathological significance in benign and malignant pancreatic lesions.
Chen XL; Xie KX; Yang ZL; Yuan LW
Int J Clin Exp Pathol; 2019; 12(6):2111-2120. PubMed ID: 31934033
[TBL] [Abstract][Full Text] [Related]
15. Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival.
Tang W; Putluri V; Ambati CR; Dorsey TH; Putluri N; Ambs S
Clin Cancer Res; 2019 Oct; 25(19):5972-5983. PubMed ID: 31296531
[TBL] [Abstract][Full Text] [Related]
16. Update on FXR Biology: Promising Therapeutic Target?
Han CY
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30013008
[TBL] [Abstract][Full Text] [Related]
17. Rethinking the bile acid/gut microbiome axis in cancer.
Phelan JP; Reen FJ; Caparros-Martin JA; O'Connor R; O'Gara F
Oncotarget; 2017 Dec; 8(70):115736-115747. PubMed ID: 29383197
[TBL] [Abstract][Full Text] [Related]
18. High Farnesoid X Receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma.
Giaginis C; Karandrea D; Alexandrou P; Giannopoulou I; Tsourouflis G; Troungos C; Danas E; Keramopoulos A; Patsouris E; Nakopoulou L; Theocharis S
Neoplasma; 2017; 64(4):633-639. PubMed ID: 28485172
[TBL] [Abstract][Full Text] [Related]
19. Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.
Giaginis C; Sampani A; Kotta-Loizou I; Giannopoulou I; Danas E; Politi E; Tsourouflis G; Kouraklis G; Patsouris E; Keramopoulos A; Nakopoulou L; Theocharis S
Pathol Oncol Res; 2018 Jul; 24(3):631-640. PubMed ID: 28808873
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
